Bimatoprost Grenod

Summary

Bimatoprost Grenod (CHEMBL5314597) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including open-angle glaucoma and ocular hypertension.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 574.7 Da · C31H46N2O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314597
Name	Bimatoprost Grenod
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	170671901
Molecular formula	C31H46N2O8
Molecular weight	574.7
InChIKey	NTQMJNDRYSYWNJ-YVRPKJJJSA-N

SMILES: CCNC(=O)CCC/C=C/C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)OC(=O)CCCCCO[N+](=O)[O-])O)O

IUPAC name: [(E,3S)-1-[(1R,2R,3S,5R)-2-[(E)-7-(ethylamino)-7-oxohept-2-enyl]-3,5-dihydroxycyclopentyl]-5-phenylpent-1-en-3-yl] 6-nitrooxyhexanoate

Also known as: Bimatoprost grenod, NCX 470, BIMATOPROST GRENOD

Patent coverage: 1 distinct patent families (3 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
open-angle glaucoma	2	MONDO:0005338	EFO:0004190
ocular hypertension	1	MONDO:0006875	EFO:1001069
glaucoma	1	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05938699	PHASE2/PHASE3	COMPLETED	Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
NCT03657797	PHASE2	COMPLETED	Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).